Prime Medicine Inc (NASDAQ: PRME) on Monday, soared 7.07% from the previous trading day, before settling in for the closing price of $4.10. Within the past 52 weeks, PRME’s price has moved between $3.28 and $9.86.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales slid by -25.00% over the last five years. The company achieved an average annual earnings per share of 24.49%. With a float of $39.57 million, this company’s outstanding shares have now reached $97.38 million.
The firm has a total of 234 workers. Let’s measure their productivity. In terms of profitability, gross margin is 94.66%, operating margin of -560.15%, and the pretax margin is -545.19%.
Prime Medicine Inc (PRME) Insider Activity
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Prime Medicine Inc is 67.03%, while institutional ownership is 38.86%. The most recent insider transaction that took place on Feb 15 ’24, was worth 20,000,000. In this transaction Director of this company bought 3,200,000 shares at a rate of $6.25, taking the stock ownership to the 3,200,000 shares. Before that another transaction happened on Feb 15 ’24, when Company’s 10% Owner bought 3,200,000 for $6.25, making the entire transaction worth $20,000,000. This insider now owns 3,200,000 shares in total.
Prime Medicine Inc (PRME) Earnings and Forecasts
According to the Wall Street analysts, stocks earnings will be around 24.49% per share during the next fiscal year.
Prime Medicine Inc (NASDAQ: PRME) Trading Performance Indicators
Prime Medicine Inc (PRME) is currently performing well based on its current performance indicators. A quick ratio of 8.23 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 893.12.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.13, a number that is poised to hit -0.39 in the next quarter and is forecasted to reach -1.41 in one year’s time.
Technical Analysis of Prime Medicine Inc (PRME)
Analysing the last 5-days average volume posted by the [Prime Medicine Inc, PRME], we can find that recorded value of 1.15 million was better than the volume posted last year of 0.98 million. As of the previous 9 days, the stock’s Stochastic %D was 65.78%. Additionally, its Average True Range was 0.32.
During the past 100 days, Prime Medicine Inc’s (PRME) raw stochastic average was set at 31.99%, which indicates a significant decrease from 64.04% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 75.44% in the past 14 days, which was lower than the 84.29% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $3.87, while its 200-day Moving Average is $5.60. Now, the first resistance to watch is $4.70. This is followed by the second major resistance level at $5.02. The third major resistance level sits at $5.32. If the price goes on to break the first support level at $4.08, it is likely to go to the next support level at $3.78. Should the price break the second support level, the third support level stands at $3.46.
Prime Medicine Inc (NASDAQ: PRME) Key Stats
Market capitalization of the company is 526.94 million based on 120,031K outstanding shares. Right now, sales total 0 K and income totals -198,130 K. The company made 590 K in profit during its latest quarter, and -45,760 K in sales during its previous quarter.
